<DOC>
	<DOCNO>NCT02777411</DOCNO>
	<brief_summary>The objective study evaluate immune response safety profile two injection EV71 vaccine administrate without adjuvant AlPO4 0.5-μg , 1-μg , 2-μg 5-μg dose ( require ) child age 3 6 year old 0.25-μg ( require ) , 0.5-μg , 1-μg 2-μg ( require ) 6 35 month old infants/toddlers .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity EV71 Vaccine Pediatric Subjects Aged 3 6 Years 6 35 Months Old</brief_title>
	<detailed_description />
	<mesh_term>Enterovirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy child age 3 6 year old ( i.e . ≥ 3 year old &lt; 7 year old ) Part A ; 6 35 month old ( i.e . ≥ 6 month old &lt; 36 month old ) Part B time first vaccination . 2 . Subject 's guardian able willing comply study procedure give write informed consent . 3 . Subject able could comply requirement protocol . 4 . Subject body temperature ≤38°C . 1 . Subject previous know exposure Enterovirus 71 ( EV71 ) . 2 . Subject history herpangina , handfootmouth disease , acute hemorrhagic conjunctivitis associate enterovirus infection past 3 month . 3 . Subject gestation &lt; 37 week . 4 . Subject birth weight &lt; 2.5 kg . 5 . Subject history hypersensitivity vaccine , history allergic disease reaction likely exacerbate component vaccine . 6 . Family history seizure progressive neurological disease . 7 . Family history congenital hereditary immunodeficiency . 8 . Severe malnutrition dysgenopathy . 9 . Major congenital defect serious chronic illness , include perinatal brain damage . 10 . Subject diagnose autoimmune disease ( e.g. , celiac disease , type I diabetes , lupus ( SLE ) , juvenile dermatomyositis , scleroderma , juvenile idiopathic arthritis ( JIA ) , immune ( idiopathic ) thrombocytopenia purpura ) . 11 . Bleeding disorder diagnose doctor significant bruising bleed difficulty IM injection blood draw . 12 . Any acute infection 7 day prior administrate first vaccination . 13 . Use investigational product ( include drug , vaccine ) within 30 day prior vaccination plan use study period . 14 . Administration attenuate live vaccine within 7 day prior vaccination . 15 . Use immunoglobulins blood product within 3 month prior vaccination plan use study period . 16 . Chronic administration ( defined &gt; 14 day ) immunosuppressant immunomodulators systemic corticosteroid within 6 month prior vaccination . 17 . Under antituberculosis prevention therapy . 18 . Any condition opinion investigator may interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vaccines</keyword>
	<keyword>Hand , Foot Mouth Disease</keyword>
	<keyword>EV71 enteroviruses vaccine</keyword>
</DOC>